Phoenix Biotech Acquisition Corp. Unit
PBAXU
PBAXU was delisted on the 7th of February, 2024.
2 hedge funds and large institutions have $5.64K invested in Phoenix Biotech Acquisition Corp. Unit in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
208% more capital invested
Capital invested by funds: $1.83K → $5.64K (+$3.81K)
100% more funds holding
Funds holding: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$3.7K |
Top Sellers
PBAXU Hedge Fund Activity: Q3 2023 in Review
2 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Phoenix Biotech Acquisition Corp. Unit (PBAXU) for Q3 2023, worth a combined $5.64K — up 208% from $1.83K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PBAXU positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Clear Street, opening a new position worth an estimated $3.7K.
- 2 institutional investors held Phoenix Biotech Acquisition Corp. Unit (PBAXU) as of Q3 2023, up from 1 in Q2 2023.
- Funds reported $5.64K of Phoenix Biotech Acquisition Corp. Unit stock for Q3 2023, up 208% quarter-over-quarter.
- 1 fund opened new Phoenix Biotech Acquisition Corp. Unit positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest Phoenix Biotech Acquisition Corp. Unit buyer in Q3 2023 was Clear Street, an estimated $3.7K added.
Based on aggregated 13F filings for Q3 2023.